Helix BioPharma Balance Sheet

Financials in millions CAD. Fiscal year is August - July.

Millions CAD. Fiscal year is Aug - Jul.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Apr '26 Apr 30, 2026	Jul '25 Jul 31, 2025	Jul '24 Jul 31, 2024	Jul '23 Jul 31, 2023	Jul '22 Jul 31, 2022	Jul '21 Jul 31, 2021
Cash & Equivalents	2.84	0.07	1.08	0.81	3.25	3.57
Cash & Short-Term Investments	2.84	0.07	1.08	0.81	3.25	3.57
Cash Growth	297.48%	-93.99%	33.79%	-75.15%	-8.78%	-15.82%
Accounts Receivable	0.03	0.12	0.05	0.06	0.28	0.35
Other Current Assets	0.12	0.22	0.32	0.13	0.16	0.1
Total Current Assets	2.99	0.41	1.46	1	3.7	4.02
Net Property, Plant & Equipment	0	0	0.03	0.03	0.04	0.05
Other Intangible Assets	18.39	18.39	-	-	-	-
Total Assets	21.38	18.8	1.49	1.03	3.73	4.07
Accounts Payable	2.66	2.88	1.58	0.88	0.94	1.47
Accrued Expenses	-	-	-	-	-	0.38
Short-Term Debt	0.36	0.34	-	-	-	-
Current Portion of Long-Term Debt	-	-	-	-	2.47	2.03
Other Current Liabilities	3.67	-	-	1	-	-
Total Current Liabilities	6.69	3.22	1.58	1.87	3.41	3.87
Long-Term Debt	-	-	-	-	-	1.58
Total Long-Term Liabilities	-	-	-	-	-	1.58
Total Liabilities	6.69	3.22	1.58	1.87	3.41	5.46
Common Stock	180.77	179.29	158.57	152.07	147.51	139.66
Additional Paid-in Capital	52.17	52.17	52.01	48.5	47.93	47.5
Retained Earnings	-218.25	-215.88	-210.67	-201.41	-195.12	-188.55
Total Common Shareholders' Equity	14.69	15.59	-0.09	-0.84	0.32	-1.39
Shareholders' Equity	14.69	15.59	-0.09	-0.84	0.32	-1.39
Total Liabilities & Equity	21.38	18.8	1.49	1.03	3.73	4.07
Total Debt	0.36	0.34	0	0	2.47	3.61
Net Cash (Debt)	2.48	-0.27	1.08	0.81	0.78	-0.05
Net Cash Growth	-	-	33.79%	3.06%	-	-
Net Cash Per Share	0.03	-0.01	0.03	0.02	0.02	-0.00
Book Value	14.69	15.59	-0.09	-0.84	0.32	-1.39
Book Value Per Share	0.19	0.28	-0.00	-0.02	0.01	-0.05
Tangible Book Value	-3.7	-2.8	-0.09	-0.84	0.32	-1.39
Tangible Book Value Per Share	-0.05	-0.05	-0.00	-0.02	0.01	-0.05